DnB Asset Management AS
- SEC CIK
- 0001456670
- Latest filing
- Aug 11, 2026
ACAD holding history
Acadia Pharmaceuticals Inc in every 13F filed by DnB Asset Management AS, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ACAD overviewAll 13F holders of ACADFull Q2 2026 holdings
- Shares (Q2 2026)
- 23,123
- Value
- $585.0K
- % of portfolio
- <0.1%
- Quarters held
- 16
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 23,123 | $585.0K | <0.1% | +4,600+24.8% | Added | Holders |
| Q1 2026 | 18,523 | $412.3K | <0.1% | +3,821+26.0% | Added | Holders |
| Q4 2025 | 14,702 | $392.7K | <0.1% | +1,525+11.6% | Added | Holders |
| Q3 2025 | 13,177 | $281.2K | <0.1% | +2,258+20.7% | Added | Holders |
| Q2 2025 | 10,919 | $235.5K | <0.1% | −4,692−30.1% | Reduced | Holders |
| Q1 2025 | 15,611 | $259.3K | <0.1% | +1,409+9.9% | Added | Holders |
| Q4 2024 | 14,202 | $260.6K | <0.1% | +3,964+38.7% | Added | Holders |
| Q3 2024 | 10,238 | $157.5K | <0.1% | +113+1.1% | Added | Holders |
| Q2 2024 | 10,125 | $164.5K | <0.1% | +10,125 | New | Holders |
| Q3 2023 | 0 | $0 | 0.0% | −12,141−100.0% | Sold out | Holders |
| Q2 2023 | 12,141 | $290.8K | <0.1% | +12,141 | New | Holders |
| Q3 2022 | 0 | $0 | 0.0% | −46,171−100.0% | Sold out | Holders |
| Q2 2022 | 46,171 | $651.0K | <0.1% | −21,471−31.7% | Reduced | Holders |
| Q1 2022 | 67,642 | $1.64M | <0.1% | −14,440−17.6% | Reduced | Holders |
| Q4 2021 | 82,082 | $1.92M | <0.1% | −8,758−9.6% | Reduced | Holders |
| Q3 2021 | 90,840 | $1.51M | <0.1% | −2,119−2.3% | Reduced | Holders |
| Q2 2021 | 92,959 | $2.27M | <0.1% | +483+0.5% | Added | Holders |
| Q1 2021 | 92,476 | $2.39M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.